Medivir
2,701 SEK -2,6%1 investor følger denne virksomhed
Medivir is a pharmaceutical company. The company develops drugs and treatments with a focus on cancers and other serious diseases. The company invests in indication areas where available treatment methods are limited or completely lacking research. Collaborations with other partners are part of the business model, and drug development, as well as commercialization, are conducted either in-house or in partnership with other pharmaceutical companies. The head office is located in Huddinge.
Omsætning
7,6 mio.
EBIT %
-1.202,63 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
MVIR
Daglig lav / høj pris
2,5 / 2,772
SEK
Markedsværdi
304,93 mio. SEK
Aktieomsætning
1,95 mio. SEK
Volumen
735 t
Seneste videoer
Finanskalender
Delårsrapport
30.04.2024
Generalforsamling
07.05.2024
Delårsrapport
22.08.2024
Delårsrapport
06.11.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Linc AB | 12,2 % | 12,2 % |
Avanza Pension | 9,8 % | 9,0 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
Medivir to present at the Life Science Day in Gothenburg on March 6
Change in Medivir's nomination committee before the 2024 AGM
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools